Growth hormone response to low-dose apomorphine in restless legs syndrome

Growth Hormone and IGF Research

Volumn 17, Issue 4, 2007, Pages 323-327

  Happe, Svenja ^a   Bachmann, Cornelius G ^a   Helmschmied, Kathrin ^a   Neubert, Karin ^a   Wuttke, Wolfgang ^a   Paulus, Walter ^a   Trenkwalder, Claudia ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b PARACELSUS ELENA KLINIK   (Germany)

Author keywords

Apomorphine; Cortisol; Growth hormone (GH); Hypothalamus; Restless legs syndrome (RLS)

Indexed keywords

APOMORPHINE; DOPAMINE RECEPTOR; GROWTH HORMONE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; RESTLESS LEGS SYNDROME; SCORING SYSTEM;

ADULT; AGED; APOMORPHINE; DOPAMINE AGONISTS; FEMALE; GROWTH HORMONE; HUMANS; HYDROCORTISONE; LEVODOPA; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME;

EID: 34547205516     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2007.04.002     Document Type: Article

References (23)

1. R. Allen, D. Picchietti, W. Hening, C. Trenkwalder, A. Walters, J. Montplaisir, Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology, in: A Report from the Restless Legs Syndrome Diagnosis and Epidemiology Workshop at the National Institute of Health, Sleep Med. 4 (2003) 101-119.
2. J. Winkelmann, T.C. Wetter, V. Collado-Seidel, T. Gasser, M. Dichgans, A. Yassouridis, C. Trenkwalder, Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients, Sleep 23 (2000) 597-602.
3. Ancoli-Israel S., Kripke D.M., Klauber M.R., Mason W.J., Fell R., and Kaplan O. Periodic limb movements in sleep in community dwelling elderly. Sleep 14 (1991) 496-500
4. Lavigne G.J., and Montplaisir J.Y. Restless legs syndrome and sleep bruxism: Prevalence and association among Canadians. Sleep 17 (1994) 739-743
5. Montplaisir J., Boucher S., Poirier G., Lavigne G., Lapierre O., and Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria. Mov. Disord. 12 (1997) 61-65
6. Phillips B., Young T., Finn L., Asher K., Hening W.A., and Purvis C. Epidemiology of restless legs symptoms in adults. Arch. Intern. Med. 160 (2000) 2137-2141
7. Rothdach A.J., Trenkwalder C., Haberstock J., Keil U., and Berger K. Prevalence and risk factors of RLS in an elderly population. The MEMO study. Neurology 54 (2000) 1064-1068
8. Walters A.S., Hickey K., Maltzman J., Verrico T., Joseph D., Hening W., Wilson V., and Chokroverty S. A questionnaire study of 138 patients with restless legs syndrome: The "night walkers" survey. Neurology 46 (1996) 92-95
9. Atlas Task Force of the American Sleep Disorders Association. Recording and scoring of leg movements, Sleep 16 (1993) 748-759.
10. Lugaresi E., Coccagna G., Tassinari C.A., and Ambrosetto C. Polygraphic data on motor phenomena in the restless legs syndrome. Rivista di Neurologia 35 (1965) 550-561
11. Symonds C.P. Nocturnal myoclonus. J. Neurol. Neurosurg. Psychiat. 16 (1953) 166-171
12. Friess E., Kümpfel T., Winkelmann J., Schmid D., Uhr M., Rupprecht R., Holsboer F., and Trenkwalder C. Increased growth hormone response to apomorphine in Parkinson's disease compared with multiple system atrophy. Arch. Neurol. 58 (2001) 241-246
13. Happe S., Tings T., Helmschmied K., Neubert K., Wuttke W., Paulus W., and Trenkwalder C. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease. Mov. Disord. 19 (2004) 1511-1521
14. Walters A.S., LeBrocq C., Dhar A., and International Restless Legs Syndrome Study Group. Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med. 4 (2003) 121-132
15. Corn T.H., Hale A.S., Thompson C., Bridges P.K., and Checkley S.A. A comparison of the growth hormone responses to clonidine and apomorphine in the same patients with endogenous depression. Br. J. Psy. 144 (1984) 636-639
16. Kraemer W.J., Dudley G.A., Tesch P.A., Gordon S.E., Hather B.M., Volek J.S., and Ratamess N.A. The influence of muscle action on the acute growth hormone response to resistance exercise and short-term detraining. Growth Horm. IGF Res. 11 (2001) 75-83
17. Brunner E., Domhof S., and Langer F. Nonparametric Analysis of Longitudinal Data in Factorial Experiments (2002), Wiley, New York
18. Veldhuis J.D. Neuroendocrine control of pulsatile growth hormone release in the human: Relationship with gender. Growth Horm. IGF Res. 8 Suppl B (1998) 49-59
19. Winkelmann J., Schadrack J., Wetter T.C., Zieglgansberger W., and Trenkwalder C. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med. 2 (2001) 57-61
20. Wetter T.C., Collado-Seidel V., Oertel W.H., Uhr M., Yassouridis A., and Trenkwalder C. Endocrine rhythms in patients with restless legs syndrome. J. Neurol. 249 (2002) 146-151
21. Garcia-Borreguero D., Larrosa O., Granizo J.J., de la Llave Y., and Henning W.A. Circadian variation in neuroendocrine response to l-dopa in patients with restless legs syndrome. Sleep 27 (2004) 669-673
22. Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 12 (1988) 117-164
23. McMahon C.D., Radcliff R.P., Lookingland K.J., and Tucker H.A. Neuroregulation of growth hormone secretion in domestic animals. Domestic Animals Endocrinology 20 (2001) 65-87